MS and Demyelinating Disorders

The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital commented on presentations given at the recent event, as well as key takeaways from his own discussion on novel imaging approaches in multiple sclerosis. [WATCH TIME: 2 minutes]

The director of Cleveland Clinic’s Epilepsy Center discussed the currently known overlap between neurological diseases and the need to identify causative biomarkers. [WATCH TIME: 4 minutes]

The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital outlined a presentation he gave at a recent Institutional Perspectives in Neurology: MS event. [WATCH TIME: 3 minutes]

Kristin Galetta, MD, MSEd, provided insight on differences between B-cell depleting disease-modifying therapies for MS and how they continue to shape the future of drug development.

The chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]

With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.

Chaired by Eric Klawiter, MD, MSc, the presentations also feature Mass General and Brigham and Women's experts Tanuja Chitnis, MD; Kristin Galetta, MD; and Michael Levy, MD, PhD. [WATCH TIME: 1 hour, 26 minutes]

The professor of neurology at Brigham and Women’s Hospital discussed her presentation on B-cell depleting therapies such as ocrelizumab and ofatumumab for the treatment of multiple sclerosis. [WATCH TIME: 2 minutes]

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending February 12, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 11, 2022.

Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]

The chief medical officer at Atara Biotherapeutics discussed the investigational agent ATA188, its mechanism to treat multiple sclerosis, and what to look for in its upcoming EMBOLD trial data readout. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Dhanashri P. Miskin, MD. [LISTEN TIME: 39 minutes]

Hamid Khoja, PhD, chief scientific officer of FibroBiologics, spoke on the development and studies of CYMS101, which the company anticipates evaluating in a larger clinical trial in 2023.

The chief medical officer at Atara Biotherapeutics detailed the clinical significance of a recently published paper in Nature that adds to the evidence that Epstein-Barr virus is the leading cause of multiple sclerosis. [WATCH TIME: 3 minutes]

Almost 40% of the studies assess did not report racial or ethnic subgroup data. Geographically, there was a slight increase in the number of South American-based phase 3 DMT trials and almost little-to-no improvement in the phase 3 DMT studies based in Africa.

Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology for this patient population, particularly the absence of adverse effects. [WATCH TIME: 3 minutes]

In addition to those with MS, the approval also indicates the formulation for the treatment of patients with spinal cord injuries and other spinal cord diseases.

The chief scientific officer of FibroBiologics spoke on fibroblast cell technology and its specific benefits in comparison stem cell therapy. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the steps needed to take to improve relatively new wellness strategies. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 4, 2022.

Although research illustrates the persistence of inequities between women and men in neurology, 3 women leaders shared encouraging thoughts and experiences highlighting the progress made in recent years.